Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated ...

Gedatolisib is the first inhibitor targeting the PI3K/AKT/mTOR (“PAM”) pathway to demonstrate positive Phase 3 results in patients with HR+/HER2-/ PIK3CA WT ABC whose disease progressed on or after ...

For the severely malnourished, simply starting to eat normal meals again can cause sickness—even death.